里桑基祖马布在克罗恩病中的有效性和安全性:来自大型三级医疗中心的现实数据
Adar Zinger1, David Choi1, Natalie Choi1
1Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois.
瑞桑基祖马布有效地准了对炎症性肠道疾病的互白素-23 (IL-23). 这项研究评估了其在克罗恩病患者的真实世界诱导有效性和安全性.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 介素-23 (IL-23) 在炎症性肠病 (IBD) 的病原发生中起着关键作用.
- 乌斯特基努马布针对IL-23和IL-12的共享p40亚单元,是IBD的第一个IL-23向剂.
- 瑞桑基祖马布通过向p19亚单元来选择性抑制IL-23.
研究的目的:
- 在诱导期内描述瑞桑基祖马布的有效性和安全性.
- 在克罗恩病 (CD) 的现实环境中评估risankizumab.
主要方法:
- 针对中度至重度活跃克罗恩病接受瑞桑基祖马布治疗的患者的回顾性分析.
- 在诱导阶段评估临床有效性和安全性结果.
主要成果:
- 瑞桑基祖马布在克罗恩病患者的诱导期表现出有效性.
- 在这个现实世界队列中,评估了risankizumab的安全性.
结论:
- 瑞桑基祖马布是克罗恩病诱导期的有效和安全的治疗选择.
- 现实世界的数据支持在IBD管理中使用risankizumab.
更多相关视频
06:19Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
